

CITATION REPORT

List of articles citing

Docosahexaenoic acid supplementation decreases liver fat content in children with non-alcoholic fatty liver disease: double-blind randomised controlled clinical trial

DOI: 10.1136/adc.2010.192401

Archives of Disease in Childhood, 2011, 96, 350-3.

Source: <https://exaly.com/paper-pdf/50171136/citation-report.pdf>

Version: 2024-04-19

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
210	Advances in pediatric nonalcoholic fatty liver disease. 2011 , 58, 1375-92, x		39
209	Hepatosteatosis in peroxisome deficient liver despite increased oxidation capacity and impaired lipogenesis. 2011 , 93, 1828-38		20
208	Effect of treatment with polyunsaturated fatty acids on HCV- or diet-induced fatty liver. 2011 , 54, 1325-6; author reply 1326		
207	Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. 2011 , 58, 2047-67		1138
206	Nonalcoholic Fatty Liver Disease in Children. 2011 , 14, 209		4
205	Biochemical parameters and anthropometry predict NAFLD in obese children. 2011 , 53, 590-3		26
204	Recent advances in biomarkers for noninvasive diagnosis of nonalcoholic steatohepatitis: the role of lipid analysis/profiling. 2011 , 6, 427-436		1
203	Supplementation of monounsaturated and polyunsaturated fatty acids in non-alcoholic fatty liver disease and metabolic syndrome. 2011 , 46, 389-90		1
202	The use of ultrasound in clinical setting for children affected by NAFLD: is it safe and accurate?. 2011 , 37, 36		5
201	Nonalcoholic fatty liver disease: Targeted therapy in children--what is the right way?. 2011 , 8, 425-6		10
200	Nonalcoholic steatohepatitis: the therapeutic challenge of a global epidemic. 2011 , 22, 479-88		86
199	Expert opinion on current therapies for nonalcoholic fatty liver disease. 2011 , 12, 1901-11		12
198	Menhaden oil decreases high-fat diet-induced markers of hepatic damage, steatosis, inflammation, and fibrosis in obese Ldlr ^{-/-} mice. 2012 , 142, 1495-503		35
197	Docosahexaenoic acid prevents trans-10, cis-12-conjugated linoleic acid-induced nonalcoholic fatty liver disease in mice by altering expression of hepatic genes regulating fatty acid synthesis and oxidation. 2012 , 10, 175-80		15
196	Docosahexaenoic acid supplementation improved lipocentric but not glucocentric markers of insulin sensitivity in hypertriglyceridemic men. 2012 , 10, 32-8		21
195	Pediatric nonalcoholic fatty liver disease: a multidisciplinary approach. 2012 , 9, 152-61		79
194	Nonalcoholic fatty liver in children and adolescents: an overview. 2012 , 51, 305-12		33

193	Effect of intrauterine growth retardation on liver and long-term metabolic risk. 2012 , 36, 1270-7	34
192	Fish oil -- how does it reduce plasma triglycerides?. 2012 , 1821, 843-51	164
191	Docosahexaenoic acid ameliorates palmitate-induced lipid accumulation and inflammation through repressing NLRC4 inflammasome activation in HepG2 cells. 2012 , 9, 34	24
190	Therapeutic options in pediatric non alcoholic fatty liver disease: current status and future directions. 2012 , 38, 55	28
189	The potential role of fatty liver in paediatric metabolic syndrome: a distinct phenotype with high metabolic risk?. 2012 , 7, e75-80	24
188	Role of fats in the first two years of life as related to later development of NCDs. 2012 , 22, 775-80	31
187	Omega-3 fatty acids for the treatment of non-alcoholic fatty liver disease. 2012 , 18, 5839-47	121
186	Increased erythrocytes n-3 and n-6 polyunsaturated fatty acids is significantly associated with a lower prevalence of steatosis in patients with type 2 diabetes. 2012 , 31, 520-5	33
185	Application of polyunsaturated fatty acids in internal medicine: beyond the established cardiovascular effects. 2012 , 8, 784-93	38
184	Cidea promotes hepatic steatosis by sensing dietary fatty acids. 2012 , 56, 95-107	117
183	Non-alcoholic fatty liver disease in children now: lifestyle changes and pharmacologic treatments. 2012 , 28, 722-6	29
182	Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. 2012 , 55, 885-904	444
181	Treatment of nonalcoholic fatty liver disease in adults and children: a closer look at the arsenal. 2012 , 47, 29-36	5
180	Pediatric non alcoholic fatty liver disease: old and new concepts on development, progression, metabolic insight and potential treatment targets. 2013 , 13, 40	107
179	Potential treatment of human nonalcoholic fatty liver disease with long-chain omega-3 polyunsaturated fatty acids. 2013 , 71, 753-71	27
178	A 360-degree overview of paediatric NAFLD: recent insights. 2013 , 58, 1218-29	120
177	Nonalcoholic fatty liver disease and the metabolic syndrome: clinical implications and treatment. 2013 , 28, 40-51	46
176	[Non-alcoholic fatty liver disease in obese children and adolescents]. 2013 , 56, 517-27	4

175	Role of diet and nutritional management in non-alcoholic fatty liver disease. 2013 , 28 Suppl 4, 81-7	92
174	Docosahexaenoic acid for the treatment of fatty liver: randomised controlled trial in children. 2013 , 23, 1066-70	93
173	Non-alcoholic fatty liver disease. 2013 , 23, 529-534	3
172	Omega-3 fatty acids for treatment of non-alcoholic fatty liver disease: design and rationale of randomized controlled trial. 2013 , 13, 85	48
171	Omega-3 polyunsaturated fatty acids for non-alcoholic fatty liver disease. 2013 ,	1
170	Paediatric nonalcoholic fatty liver disease. 2013 , 29, 279-84	17
169	A meal high in saturated fat evokes postprandial dyslipemia, hyperinsulinemia, and altered lipoprotein expression in obese children with and without nonalcoholic fatty liver disease. 2013 , 37, 517-28	21
168	Estimation of fish and ω fatty acid intake in pediatric nonalcoholic fatty liver disease. 2013 , 57, 627-33	24
167	Ursodeoxycholy l lysophosphatidylethanolamide inhibits lipoapoptosis by shifting fatty acid pools toward monosaturated and polyunsaturated fatty acids in mouse hepatocytes. 2013 , 84, 696-709	15
166	Omega-3 fatty acids for the treatment of nonalcoholic fatty liver disease in children and adolescents. 2013 , 8, 509-512	
165	A critical appraisal of advances in pediatric nonalcoholic Fatty liver disease. 2012 , 32, 317-24	17
164	The I148M variant of PNPLA3 reduces the response to docosahexaenoic acid in children with non-alcoholic fatty liver disease. 2013 , 16, 957-60	49
163	Oxidized metabolites of linoleic acid as biomarkers of liver injury in nonalcoholic steatohepatitis. 2013 , 8, 411-418	18
162	Manifestations of fasting-induced fatty liver and rapid recovery from steatosis in voles fed lard or flaxseed oil lipids. 2013 , 5, 4211-30	7
161	Nutritional management of insulin resistance in nonalcoholic fatty liver disease (NAFLD). 2013 , 5, 4093-114	47
160	Dietary anthocyanins as nutritional therapy for nonalcoholic fatty liver disease. 2013 , 2013, 145421	81
159	Role of docosahexaenoic acid treatment in improving liver histology in pediatric nonalcoholic fatty liver disease. 2014 , 9, e88005	94
158	Reduced dietary omega-6 to omega-3 fatty acid ratio and 12/15-lipoxygenase deficiency are protective against chronic high fat diet-induced steatohepatitis. 2014 , 9, e107658	36

157	Current pharmacotherapy for treating pediatric nonalcoholic fatty liver disease. 2014 , 15, 2501-11	6
156	Chemoprevention of nonalcoholic fatty liver disease by dietary natural compounds. 2014 , 58, 147-71	63
155	Randomised clinical trial: The beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis. 2014 , 39, 1276-85	269
154	Nonalcoholic fatty liver disease: diagnosis, pathogenesis, and management. 2014 , 25, 127-32	29
153	Using high-dose omega-3 fatty acid supplements to lower triglyceride levels in 10- to 19-year-olds. 2014 , 53, 428-38	34
152	Pediatric non-alcoholic fatty liver disease: an increasing public health issue. 2014 , 173, 131-9	84
151	A non-invasive prediction model for non-alcoholic steatohepatitis in paediatric patients with non-alcoholic fatty liver disease. 2014 , 46, 1008-13	16
150	N-3 long-chain PUFA supplementation prevents high fat diet induced mouse liver steatosis and inflammation in relation to PPAR- γ upregulation and NF- κ B DNA binding abrogation. 2014 , 58, 1333-41	62
149	A double-blind randomized trial of fish oil to lower triglycerides and improve cardiometabolic risk in adolescents. 2014 , 165, 497-503.e2	32
148	Review article: the management of paediatric nonalcoholic fatty liver disease. 2014 , 40, 1155-70	33
147	Design and rationale of the WELCOME trial: A randomised, placebo controlled study to test the efficacy of purified long chain omega-3 fatty acid treatment in non-alcoholic fatty liver disease [corrected]. 2014 , 37, 301-11	39
146	Paediatric non-alcoholic fatty liver disease: an overview. 2015 , 16, 393-405	38
145	Dietary supplements and pediatric non-alcoholic fatty liver disease: Present and the future. 2015 , 7, 2597-602	38
144	Valproic acid and nonalcoholic fatty liver disease: A possible association?. 2015 , 7, 1251-7	34
143	Oily fish, coffee and walnuts: Dietary treatment for nonalcoholic fatty liver disease. 2015 , 21, 10621-35	30
142	PAEDIATRIC NON ALCOHOLIC FATTY LIVER DISEASE: AN EMERGING THREAT. 2015 , 11, 1-9	4
141	Fatty acid desaturase 1 gene polymorphisms control human hepatic lipid composition. 2015 , 61, 119-28	47
140	Adipose tissue dysregulation and metabolic consequences in childhood and adolescent obesity: potential impact of dietary fat quality. 2015 , 74, 67-82	29

139	Long-Term Treatment with n-3 Polyunsaturated Fatty Acids as a Monotherapy in Children with Nonalcoholic Fatty Liver Disease. 2015 , 7, 121-7	46
138	A double-blind, placebo-controlled randomized trial to evaluate the efficacy of docosahexaenoic acid supplementation on hepatic fat and associated cardiovascular risk factors in overweight children with nonalcoholic fatty liver disease. 2015 , 25, 734-41	60
137	Omega-3 Fatty acids therapy in children with nonalcoholic Fatty liver disease: a randomized controlled trial. 2015 , 166, 1358-63.e1-3	80
136	Pros and cons of fatty acids in bone biology. 2015 , 58, 121-45	22
135	The use of omega-3 Fatty acids in nonalcoholic Fatty liver disease: the end of the road or a new beginning?. 2015 , 166, 1335-7	4
134	Plasma fatty acid composition in French-Canadian children with non-alcoholic fatty liver disease: Effect of n-3 PUFA supplementation. 2015 , 99, 25-34	24
133	Double-blind randomized placebo-controlled clinical trial of omega 3 fatty acids for the treatment of diabetic patients with nonalcoholic steatohepatitis. 2015 , 49, 137-44	112
132	Beneficial effects of Ω PUFA in children on cardiovascular risk factors during childhood and adolescence. 2015 , 120, 72-9	27
131	Nonalcoholic Fatty Liver Disease and Fibrosis in Youth Taking Psychotropic Medications: Literature Review, Case Reports, and Management. 2015 , 25, 602-10	4
130	Docosahexaenoic acid attenuates Western diet-induced hepatic fibrosis in Ldlr ^{-/-} mice by targeting the TGF β Smad3 pathway. 2015 , 56, 1936-46	29
129	Treating liver fat and serum triglyceride levels in NAFLD, effects of PNPLA3 and TM6SF2 genotypes: Results from the WELCOME trial. 2015 , 63, 1476-83	66
128	Potential for dietary Ω fatty acids to prevent nonalcoholic fatty liver disease and reduce the risk of primary liver cancer. 2015 , 6, 694-702	49
127	A Guide to Non-Alcoholic Fatty Liver Disease in Childhood and Adolescence. 2016 , 17,	100
126	In vitro Modulation of the LPS-Induced Proinflammatory Profile of Hepatocytes and Macrophages- Approaches for Intervention in Obesity?. 2016 , 4, 61	9
125	Macrophage Activation in Pediatric Nonalcoholic Fatty Liver Disease (NAFLD) Correlates with Hepatic Progenitor Cell Response via Wnt3a Pathway. 2016 , 11, e0157246	41
124	Omega-3 Fatty Acid-Rich Parenteral Nutrition: Is It a Double-Edged Sword?. 2016 , 62, e47	
123	A post-weaning fish oil dietary intervention reverses adverse metabolic outcomes and 11 β hydroxysteroid dehydrogenase type 1 expression in postnatal overfed rats. 2016 , 116, 1519-1529	7
122	Impact of dietary fat on the development of non-alcoholic fatty liver disease in Ldlr ^{-/-} mice. 2016 , 75, 1-9	29

121	Lifestyle Interventions Including Nutrition, Exercise, and Supplements for Nonalcoholic Fatty Liver Disease in Children. 2016 , 61, 1375-86	60
120	Association between erythrocyte omega-3 polyunsaturated fatty acid levels and fatty liver index in older people is sex dependent. 2016 , 5, 78-85	7
119	Pediatric Non-alcoholic Fatty Liver Disease. 2016 , 18, 24	26
118	Treatment of Nonalcoholic Fatty Liver Disease with Long-Chain n-3 Polyunsaturated Fatty Acids in Humans. 2016 , 14, 417-430	18
117	One month of omega-3 fatty acid supplementation improves lipid profiles, glucose levels and blood pressure in overweight schoolchildren with metabolic syndrome. 2016 , 29, 1143-1150	19
116	Clinical advances in pediatric nonalcoholic fatty liver disease. 2016 , 63, 1718-25	35
115	Omega-3 Fatty Acid-rich Parenteral Nutrition: Is It a Double-edged Sword?. 2016 , 62, e46-7	
114	Impact of anti-inflammatory nutrients on obesity-associated metabolic-inflammation from childhood through to adulthood. 2016 , 75, 115-24	32
113	Pro-resolving mediators produced from EPA and DHA: Overview of the pathways involved and their mechanisms in metabolic syndrome and related liver diseases. 2016 , 785, 133-143	60
112	Pediatric liver diseases: current challenges and future perspectives. 2016 , 10, 255-65	13
111	Alcoholic and Non-Alcoholic Fatty Liver Disease. 2016 ,	3
110	Comparison of the Phenotype and Approach to Pediatric vs Adult Patients With Nonalcoholic Fatty Liver Disease. 2016 , 150, 1798-810	84
109	Similarities and differences between pediatric and adult nonalcoholic fatty liver disease. 2016 , 65, 1161-71	43
108	Exercise and diet in the management of nonalcoholic fatty liver disease. 2016 , 65, 1172-82	37
107	Nonalcoholic Fatty Liver Disease. 2016 , 753-774	
106	Nutritional therapy for nonalcoholic fatty liver disease. 2016 , 29, 1-11	72
105	Omega-3 fatty acids: Mechanisms of benefit and therapeutic effects in pediatric and adult NAFLD. 2016 , 53, 106-20	28
104	The role of nutraceuticals for the treatment of non-alcoholic fatty liver disease. 2017 , 83, 88-95	54

103	Plin5 alleviates myocardial ischaemia/reperfusion injury by reducing oxidative stress through inhibiting the lipolysis of lipid droplets. 2017 , 7, 42574	37
102	Systematic Review: Nutrition and Physical Activity in the Management of Paediatric Nonalcoholic Fatty Liver Disease. 2017 , 65, 141-149	29
101	NASPGHAN Clinical Practice Guideline for the Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease in Children: Recommendations from the Expert Committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN). 2017 , 64, 319-334	382
100	Omega-3 Fatty Acids and Incident Ischemic Stroke and Its Atherothrombotic and Cardioembolic Subtypes in 3 US Cohorts. 2017 , 48, 2678-2685	37
99	Atorvastatin reduces lipid accumulation in the liver by activating protein kinase A-mediated phosphorylation of perilipin 5. 2017 , 1862, 1512-1519	13
98	Nonalcoholic fatty liver disease, association with cardiovascular disease and treatment (II). The treatment of nonalcoholic fatty liver disease. 2017 , 29, 185-200	
97	Monitoring the efficacy of omega-3 supplementation on liver steatosis and carotid intima-media thickness: a pilot study. 2017 , 3, 201-211	3
96	The pharmacological management of NAFLD in children and adolescents. 2017 , 10, 1225-1237	9
95	Oxidative Stress as a Critical Factor in Nonalcoholic Fatty Liver Disease Pathogenesis. 2017 , 26, 519-541	213
94	Nonalcoholic fatty liver disease, association with cardiovascular disease and treatment (II). The treatment of nonalcoholic fatty liver disease. 2017 , 29, 185-200	6
93	SUPPLEMENTATION WITH 2:1 RATIO OF N-6:N-3 POLYUNSATURATED FATTY ACID IMPROVES LIVER STEATOSIS AND SERUM CYTOKINE LEVELS IN YOUNG OBESE BALINESE WOMEN: A RANDOMIZED CLINICAL TRIAL. 2017 , 10, 74	
92	A Review of Recruitment, Adherence and Drop-Out Rates in Omega-3 Polyunsaturated Fatty Acid Supplementation Trials in Children and Adolescents. 2017 , 9,	18
91	Mediterranean Diet and Multi-Ingredient-Based Interventions for the Management of Non-Alcoholic Fatty Liver Disease. 2017 , 9,	47
90	Vitamin D Supplementation and Non-Alcoholic Fatty Liver Disease: Present and Future. 2017 , 9,	33
89	The Role of Lipid and Lipoprotein Metabolism in Non-Alcoholic Fatty Liver Disease. 2017 , 4,	49
88	The Role of Tissue Macrophage-Mediated Inflammation on NAFLD Pathogenesis and Its Clinical Implications. 2017 , 2017, 8162421	85
87	Non-alcoholic fatty liver disease severity and metabolic complications in obese children: impact of omega-3 fatty acids. 2018 , 58, 28-36	21
86	Fatty Liver Disease. 2018 , 451-462	

85	Oleic acid protects saturated fatty acid mediated lipotoxicity in hepatocytes and rat of non-alcoholic steatohepatitis. 2018 , 203, 291-304	59
84	Omega-3 fatty acids and non-alcoholic fatty liver disease: Evidence of efficacy and mechanism of action. 2018 , 64, 135-146	61
83	Omega-3 fatty acids as a treatment for non-alcoholic fatty liver disease in children: A systematic review and meta-analysis of randomized controlled trials. 2018 , 37, 516-521	38
82	Non-alcoholic fatty liver disease and its treatment with n-3 polyunsaturated fatty acids. 2018 , 37, 37-55	66
81	Omega-3 polyunsaturated fatty acids as a treatment strategy for nonalcoholic fatty liver disease. 2018 , 181, 108-125	64
80	Dietary omega-3 and omega-6 polyunsaturated fatty acids modulate hepatic pathology. 2018 , 52, 92-102	28
79	Omega-3 polyunsaturated fatty acid supplementation and non-alcoholic fatty liver disease: A meta-analysis of randomized controlled trials. 2018 , 97, e12271	55
78	Effective Food Ingredients for Fatty Liver: Soy Protein & Conglycinin and Fish Oil. 2018 , 19,	8
77	Adipose tissue polyunsaturated fatty acids and metabolic syndrome among adult parents and their children. 2018 , 28, 1237-1244	3
76	Obesity Development in a Miniature Yucatan Pig Model: A Multi-compartmental Metabolomics Study on Cloned and Normal Pigs Fed Restricted or Ad Libitum High-Energy Diets. 2019 , 18, 30-47	10
75	Pharmacological interventions for non-alcoholic fatty liver disease: a systematic review and network meta-analysis. 2018 , 94, 556-565	11
74	Omega-3 fatty acids does not affect physical activity and body weight in primary school children - a double-blind randomized placebo-controlled trial. 2018 , 8, 12725	4
73	Omega-3 Fatty Acids and Fatty Liver Disease in Children. 2018 , 85, 59-77	3
72	Metabolomic analysis of cholestatic liver damage in mice. 2018 , 120, 253-260	10
71	Nonalcoholic Fatty Liver Disease in Children: Not a Small Matter. 2018 , 20, 315-329	16
70	Science behind the cardio-metabolic benefits of omega-3 polyunsaturated fatty acids: biochemical effects vs. clinical outcomes. 2018 , 9, 3576-3596	38
69	Systematic review and meta-analysis of controlled intervention studies on the effectiveness of long-chain omega-3 fatty acids in patients with nonalcoholic fatty liver disease. 2018 , 76, 581-602	49
68	Diet as moderator in the association of adiposity with inflammatory biomarkers among adolescents in the HELENA study. 2019 , 58, 1947-1960	12

67	Diet as a moderator in the association of sedentary behaviors with inflammatory biomarkers among adolescents in the HELENA study. 2019 , 58, 2051-2065	12
66	Evaluations of Lifestyle, Dietary, and Pharmacologic Treatments for Pediatric Nonalcoholic Fatty Liver Disease: A Systematic Review. 2019 , 17, 1457-1476.e7	23
65	Serum Polyunsaturated Fatty Acids in Middle Childhood and Body Mass Index Change Through Adolescence. 2019 , 75, 77-85	1
64	NAFLD in children: new genes, new diagnostic modalities and new drugs. 2019 , 16, 517-530	105
63	A Lipidomic Analysis of Docosahexaenoic Acid (22:6, β) Mediated Attenuation of Western Diet Induced Nonalcoholic Steatohepatitis in Male Mice. 2019 , 9,	9
62	Plin3 protects against alcoholic liver injury by facilitating lipid export from the endoplasmic reticulum. 2019 , 120, 16075-16087	12
61	Non-alcoholic fatty liver infiltration in children: an underdiagnosed evolving disease. 2019 , 18, 255-265	3
60	Fish, Shellfish, and Children's Health: An Assessment of Benefits, Risks, and Sustainability. 2019 ,	12
59	Epigenetic Effects of n-3 LCPUFAs: A Role in Pediatric Metabolic Syndrome. 2019 , 20,	15
58	Impact of Nutritional Changes on Nonalcoholic Fatty Liver Disease. 2019 , 11,	71
57	Dietary Management of Nonalcoholic Fatty Liver Disease (NAFLD) by n-3 Polyunsaturated Fatty Acid (PUFA) Supplementation. 2019 , 373-389	2
56	Dietary Interventions in Fatty Liver. 2019 , 245-255	
55	Effect of omega-3 fatty acids supplementation combined with lifestyle intervention on adipokines and biomarkers of endothelial dysfunction in obese adolescents with hypertriglyceridemia. 2019 , 64, 162-169	15
54	Role of Nutrition in the Pathogenesis and Prevention of Non-alcoholic Fatty Liver Disease: Recent Updates. 2019 , 15, 265-276	41
53	Rates of and Factors Associated With Placebo Response in Trials of Pharmacotherapies for Nonalcoholic Steatohepatitis: Systematic Review and Meta-analysis. 2019 , 17, 616-629.e26	53
52	Treatment of Metabolic Syndrome in Children. 2020 , 93, 215-225	4
51	Pediatric Non-Alcoholic Fatty Liver Disease: Nutritional Origins and Potential Molecular Mechanisms. 2020 , 12,	11
50	Fructose, Omega 3 Fatty Acids, and Vitamin E: Involvement in Pediatric Non-Alcoholic Fatty Liver Disease. 2020 , 12,	4

49	Lifestyle modifications with anti-neuroinflammatory benefits in the aging population. 2020 , 142, 111144	5
48	Effect of Fish Oil on Insulin Sensitivity in Children: A Systematic Review and Meta-Analysis of Randomized, Controlled Trials. 2021 , 45, 531-538.e1	1
47	Association between 12-hydroxylated bile acids and hepatic steatosis in rats fed a high-fat diet. 2020 , 83, 108412	11
46	Nonalcoholic Fatty Liver Disease in Children: Unique Considerations and Challenges. 2020 , 158, 1967-1983.e1	37
45	Supplementation with Docosahexaenoic Acid and Vitamin E Improves Hepatic Triglyceride Accumulation Induced by High-Fat Diet in Mice. 2021 , 123, 2000224	1
44	Position Statement on Fat Consumption and Cardiovascular Health - 2021. 2021 , 116, 160-212	4
43	Nutraceuticals for Non-alcoholic Fatty Liver Disease. 2021 , 141-165	
42	G protein-coupled receptors: Key molecules in metabolic associated fatty liver disease development. 2021 , 87, 70-79	2
41	Advances in the Epidemiology, Diagnosis, and Management of Pediatric Fatty Liver Disease. 2021 , 43, 438-454	3
40	Free Fatty Acid Receptors as Mediators and Therapeutic Targets in Liver Disease. 2021 , 12, 656441	5
39	Non-Alcoholic Fatty Liver Disease in Obese Youth With Insulin Resistance and Type 2 Diabetes. 2021 , 12, 639548	11
38	Non-alcoholic fatty liver disease in obese children and adolescents: a role for nutrition?. 2021 ,	7
37	Nutritional supplementation for nonalcohol-related fatty liver disease: a network meta-analysis. 2021 , 7, CD013157	2
36	KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease. 2021 , 27, 363-401	21
35	Dose- and Time-Dependent Effects of Oleate on Mitochondrial Fusion/Fission Proteins and Cell Viability in HepG2 Cells: Comparison with Palmitate Effects. 2021 , 22,	2
34	Lipid Modifiers and NASH: Statins, Ezetimibe, Fibrates, and Other Agents. 293-307	3
33	Nonalcoholic Fatty Liver Disease in Children. 2016 , 339-362	1
32	A metabolomic analysis of omega-3 fatty acid-mediated attenuation of western diet-induced nonalcoholic steatohepatitis in LDLR ^{-/-} mice. 2013 , 8, e83756	36

31	Fish Oil Supplements Lower Serum Lipids and Glucose in Correlation with a Reduction in Plasma Fibroblast Growth Factor 21 and Prostaglandin E2 in Nonalcoholic Fatty Liver Disease Associated with Hyperlipidemia: A Randomized Clinical Trial. 2015 , 10, e0133496	58
30	Effectiveness of Omega-3 Polyunsaturated Fatty Acids in Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials. 2016 , 11, e0162368	57
29	Docosahexanoic Acid Plus Vitamin D Treatment Improves Features of NAFLD in Children with Serum Vitamin D Deficiency: Results from a Single Centre Trial. 2016 , 11, e0168216	56
28	Docosahexaenoic acid blocks progression of western diet-induced nonalcoholic steatohepatitis in obese Ldlr ^{-/-} mice. 2017 , 12, e0173376	32
27	Carrot Juice Administration Decreases Liver Stearoyl-CoA Desaturase 1 and Improves Docosahexaenoic Acid Levels, but Not Steatosis in High Fructose Diet-Fed Weanling Wistar Rats. 2016 , 21, 171-180	9
26	Pediatric nonalcoholic fatty liver disease, metabolic syndrome and cardiovascular risk. 2011 , 17, 3082-91	89
25	7. The role of diet in systemic and neural inflammation in obesity and metabolic syndrome. 2017 , 131-166	
24	Treatment of Nonalcoholic Fatty Liver Disease in Children: A Systematic Review. 2017 , 6,	
23	Pharmaconutrition strategy to resolve SARS-CoV-2-induced inflammatory cytokine storm in non-alcoholic fatty liver disease: Omega-3 long-chain polyunsaturated fatty acids. 2021 , 9, 9333-9349	0
22	Effects of Oxidant-Antioxidant and Vitamin D Levels on Clinical and Laboratory Data in Children With Fatty Liver Disease. 2020 , 12, e11849	1
21	Metabolic syndrome in children. 2020 , 72, 312-325	1
20	Omega-3s and cardiovascular health. 2014 , 14, 399-412	22
19	Overview of Updated Practice Guidelines for Pediatric Nonalcoholic Fatty Liver Disease. 2018 , 14, 407-414	8
18	Omega-3 for nonalcoholic fatty liver disease in children. 2019 , 65, 34-38	1
17	Nutraceuticals in Paediatric Patients with Dyslipidaemia.. 2022 , 14,	1
16	Pharmacotherapy for Non-Alcoholic Fatty Liver Disease: Emerging Targets and Drug Candidates.. 2022 , 10,	2
15	DHA Suppresses Hepatic Lipid Accumulation in Zebrafish.. 2021 , 8, 797510	1
14	Excessive Aurantiochytrium acetophilum docosahexaenoic acid supplementation decreases growth performance and breast muscle mass of broiler chickens. 2022 , 63, 102648	0

13	Metabolic Associated Fatty Liver Disease in Children-From Atomistic to Holistic.. 2021 , 9,		1
12	Can omega-3 fatty acids be beneficial in pediatric NAFLD? A systematic review and meta-analysis.. 2022 , 1-9		1
11	Liver Steatosis: A Marker of Metabolic Risk in Children.. 2022 , 23,		1
10	The Role of Macronutrients in the Pathogenesis, Prevention and Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD) in the Paediatric Population: A Review. <i>Life</i> , 2022 , 12, 839	3	1
9	Omega-3 fatty acids and metabolic partitioning of fatty acids within the liver in the context of nonalcoholic fatty liver disease. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2022 , 25, 248-255	3.8	1
8	Metabolic dysfunction-associated fatty liver disease in obese youth with insulin resistance and type 2 diabetes. <i>Current Opinion in Pediatrics</i> , 2022 , 34, 414-422	3.2	1
7	Comparative efficacy of different treatment modalities in the management of pediatric non-alcoholic fatty liver disease: A systematic review and network meta-analysis. 2022 , 108294		0
6	Bioactive compounds in childhood obesity and associated metabolic complications: Current evidence, controversies and perspectives. 2023 , 187, 106599		1
5	Effects of the Novel LaPLa-Enriched Medium- and Long-Chain Triacylglycerols on Body Weight, Glycolipid Metabolism, and Gut Microbiota Composition in High Fat Diet-Fed C57BL/6J Mice. 2023 , 28, 722		0
4	Special Population. 2023 , 27, 471-482		0
3	Nutritional Treatment of Hypertriglyceridemia in Childhood: From Healthy-Heart Counselling to Life-Saving Diet. 2023 , 15, 1088		1
2	Children with Chronic Liver Disease. 2023 , 69-87		0
1	Long-Chain Polyunsaturated Fatty Acids Effects on Cardiovascular Risk in Childhood: A Narrative Review. 2023 , 15, 1661		0